Emerging antibody-based therapies for the treatment of acute myeloid leukemia

Acute Myeloid Leukemia (AML) is a clonal malignant neoplasm of the hematopoietic system that is characterized by the infiltration of the bone marrow with immature progenitor cells that replace hematopoiesis [1]. It is a disease with heterogenous morphology, immunophenotypes, genetic aberrations, epigenetic signatures, therapy response and patient outcome [2,3]. First line therapeutic approaches in AML are based on chemotherapy, hypomethylating agents and allogeneic hematopoietic stem cell transplantation (HSCT) depending on the ability of the patient to tolerate intensive therapy and on the disease-associated risk of induction failure and relapse [4,5].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research